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ABSTRACT 
Objectives: Determine the strengths and weakness of a symptomatic screening for COVID-19 in pregnant women. Analyze 
the clinical presentation, management, and outcomes. Design: Descriptive retrospective observational study. Setting: 
Mancha-Centro Hospital (Spain).
Material and methods: Population: Symptomatic pregnant women with confirmed diagnosis of COVID-19. Between the 12th 
of March and 17th of April 2020, all the symptomatic pregnancies were screened with diagnostic test for SARS-CoV-2. Data 
collection was done by reviewing the medical records and telephone interviews. Main outcome measures: Clinical char-
acteristics, management, treatment, and obstetric and neonatal outcomes. 
Results: Twenty patients with positive COVID-19 diagnostic test out of thirty-four suspected. The most common symptoms 
were fever (70%), cough (65%) and myalgia (35%). A unique symptom of presentation in 20% of cases. COVID-19 pneumonia 
was diagnosed in 30% by chest X-ray and one case had pulmonary embolism associated diagnosed by CT-Scan. Thrombo-
prophylaxis was indicated in 16 out of 20 patients. Eight women finished their pregnancy during the observation period. 
Type of birth: 25% natural birth, 12.5% assisted vaginal delivery and 62.5% caesarean section. We had three severe cases, 
two of them with intensive care support. All neonates had negative test for COVID-19 infection.
Conclusions: We recommend universal screening of all pregnant woman for COVID-19 during the pandemic because of 
the limits of the symptomatic screening seen in this studio and the ratio of asymptomatic pregnancies with positive test 
for COVID-19 recently published. 
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INTRODUCTION  
The World Health Organization (WHO) designates COV-
ID-19 as a new disease caused by the virus severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. This 
infection was defined as a pandemic the 11th of March of 
2020 because of the alarming levels of spread and severity 
of the disease [2]. 
Spain is second in the world in number of infections 
with around 223,000 [3]. It is the first country in mortality 
with a ratio of 48.21 deaths per 100,000 population [3]. That 
means a lethality of the virus is 10.2%, reviewing the data 
collected until the 25th of April [3]. 
Our center, Hospital Mancha Centro, is one of the four-
teen placed in a region of Spain called Castilla La Mancha. 
This area is one of the ¨hot spots¨ of the pandemic in Spain. 
With a mortality ratio of 174 deaths per 100,000 population, it 
represents 11 of each 100 deaths of COVID-19 in Spain, num-
bers found similar in the most devastated areas worldwide. 
Our hospital has one of the highest ratio of hospitalizations 
per population in Spain reaching the maximum of 4.34 hospi-
talized patients per 1,000 population the past 4th of April [4]. 
The management of the obstetric population during the 
pandemic is a big challenge because of the limited specific 
information (based in case series reports about pregnancy 
and COVID-19 [5–8]), the need for hospital monitoring dur-
ing pregnancy and the necessary incomes for labour with 
the risk of infection that implies access to the hospital during 
the pandemic. 
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What remains to be clear are the clinical characteristics 
of the obstetric population infected by SARS-CoV-2, the real 
risks of vertical transmission, course of medical treatment, 
obstetric management, the balance of risk/benefit of mater-
nal breastfeeding and quarantine appliance to mother-new-
born [9–15]. To clarify this gap, we present our descriptive 
study analyzing the clinical presentation, management and 
obstetric — neonates outcomes of symptomatic pregnant 
woman with confirmed positive test for COVID-19.  
MATERIAL AND METHODS   
Study design and population
This article presents a descriptive retrospective observa-
tional study on a non-probabilistic sample of symptomatic 
pregnant women with confirmed diagnosis of COVID-19 in-
fection seen at a secondary hospital between the 12th of 
March and the 17th of April 2020. 
The inclusion criteria were all pregnancies with a con-
firmed COVID-19 infection diagnosed by qualitative sero-
logical positive antibody test and/or detection of real-time 
reverse transcription polymerase chain reaction (RT-PCR) 
from a nasopharyngeal exudate sample. All patients were 
selected, in various pregnancy trimesters or puerperal 
period, for carrying out the diagnostic tests if they pre-
sented any of the following symptoms compatible with the 
SARS-CoV-2 infection: fever over 37.8oC, cough, dyspnea, 
dysgeusia, anosmia, headache or myalgia. There were no 
exclusion criteriums. 
Positive cases were closely monitored (by phone or in 
consultation) following the new protocol designed in the 
obstetrics department of the Mancha-Centro Hospital. All 
the complementary studies done (complete blood count, 
biochemistry, C-reactive protein, D-dimer, chest X-ray or CT 
scan) and the specific treatment measures were prescribed 
according to the clinical needs of each patient. Antenatal 
corticoids treatment for fetal lung maturation were indi-
cated without changing our habitual protocol of preterm 
pregnancy up until 34 weeks. Thromboprophylaxis treat-
ment with low molecular weight (LMW) heparin was indi-
cated following the recommendations of the International 
Society of Thrombosis and Hemostasis [16] and the Spanish 
Society of Gynecology and Obstetrics [17].
Birth and puerperium of the positive patients was done 
in a specific isolated delivery room by an obstetric team 
formed by a midwife and a gynecologist, with personal 
protective equipment (PPE). The newborns were separated 
from the mothers after birth and studied by nasopharyngeal 
exudate sample, analyzed for SARS-CoV-2 by RT-PCR. If the 
companion of the pregnant women, studied by diagnostic 
test, was negative for COVID-19, they had the possibility to 
be with their newborn during the isolated hospital admis-
sion. Breastfeeding was discouraged until a negative result 
of the maternal RT-PCR. To maintain the stimulation during 
mother-child quarantine, breast pump extraction was per-
formed, and breast milk was discarded. 
Data collection 
The information for the study was collected in two steps: 
review of the medical records and by telephone interview. 
Through the clinical history we reassessed the dates of birth 
and pregnancy, gestational age at birth, laboratory testing, 
needs of intensive care or hospitalization, treatment for the 
COVID-19 infection, complications (during pregnancy or 
birth and puerperium), type of anesthesia used during labor, 
method of birth, weight of the newborn, Apgar score, type 
of neonatal reanimation, skin to skin contact, type of cord 
clamping and lactation. All of the information was recorded 
in a personalized data form for each patient. After the first re-
viewing step, the clinical data was re-evaluated by telephone 
interview, making an overhaul of the items of the clinical his-
tory, and finishing with a re-examination of the compliance 
with treatment and recommendations given at discharge.  
The starting date of COVID-19 infection was considered 
when the patient reported the beginning of the symp-
toms. The pneumonia diagnostic criteriums were based in 
radiologic findings and its severity defined by the recom-
mendations of the Infectious Diseases Society of Ameri-
ca/American Thoracic Society (IDSA/ATS) [18].
The severe cases follow at least one of the next clinical 
criteriums: severe respiratory distress, respiratory failure 
requiring mechanical ventilation or shock and organ failure 
requiring intensive care. 
Statistical analysis
Continuous variables were expressed as means with 
their standard deviation (SD). For the quantitative variables 
we defined their absolute and relative frequencies. All the 
statistical analysis is descriptive and has been carried out 
using the statistical software SPSS v24.0. 
No funding supports this study. 
RESULTS
The total number of pregnant women with 
COVID-19 (confirmed by laboratory tests) was 20 out of 
34 suspected cases with compatible clinic. The medium 
age of the patients was 34.9 years (SD = 5.00). Among all 
the infected pregnancies, 55% (11/20) were in their third 
trimester of gestation and 40% (8/20) gave birth during 
the study period. 
Clinical features 
The most common symptoms were fever over 37.8oC 
present in 70% (14/20), cough in 65% (13/20) and myal-
gia in 35% (7/20). We studied the proportion of cases with 
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multiple symptoms compared to patients with one isolated 
symptom and we found that 20% (4/20) of them had one 
unique symptom (fever 2/20 and myalgia 2/20). 
On the date of diagnosis of COVID-19 infection, the 
media of the laboratory tests were: Lymphocytes 1.66 103/µL 
(SD = 0.68), D-dimer 2.04 µg/mL (SD = 3.36) and C-Reactive 
Protein (CRP) 5.10 mg/dL (SD = 7.64). 
The analysis of the relationship between symptoms 
and complementary studies showed that in the pregnan-
cies with dyspnea the 66.7% (2/3) presented a radiologic 
diagnosis of COVID-19 pneumonia. When we compared 
the laboratory tests with each symptom, we found that the 
lowest value of lymphocytes with a media of 1.00 (SD = 0.10) 
was in the dyspnea patients while the highest values of 
D-dimer and CRP were in the pregnancies with myalgia 
with a media of 5.56 (SD = 6.03) and 9.80 (SD = 12.22) 
respectively. 
All the clinical characteristics and their relationship with 
the complementary studies are shown in Table 1. 
Regarding the transmission of the disease, 50% (10/20) 
of the pregnancies reported an unknown origin, 35% (7/20) 
had contact with a symptomatic person and 15% (3/20) 
assured that the risk of infection was inside the hospital. 
The diagnosis was stablished by qualitative serologic 
tests in 12 of the 15 cases and by RT-PCR in 11 of the 13 pa-
tients in which they were done. In 10 patients we made chest 
X-rays, finding 60% (6/10) radiologic images compatible 
with COVID-19 pneumonia (Tab. 2., Fig. 1).
Hospital admissions were 40% (8/20) of the patients and 
related to labour or maternal disease. Most of the pregnan-
cies 70% (14/20) hadn´t had any pregestational pathology. 
As remarkable risks, two patients with obesity (body mass 
index over 30 Kg/m2) and another two smokers. Also, two 
patients had preeclampsia as a relevant pregnancy disease. 
Prophylaxis of thromboembolic events with LMW hepa-
rin was prescribed in 80% (16/20) of the patients. 
Obstetric results and newborn outcomes
Eight women, positive for COVID-19, finished their preg-
nancy during the observation period. Two of them before 
34 weeks of gestation, three between 34–37 weeks and 
another three on term. From them, 87.5% (7/8) presented 
normal prenatal growth and morphological ultrasound. 
We found only one case of intrauterine growth restriction 
associated with severe preeclampsia. 
Regarding the type of delivery, 25% (2/8) had a natural 
birth, 12.5% (1/8) an assisted vaginal birth and 62.5% (5/8) 
finished on cesarean section. There weren´t any cases of 
induction of labour on maternal benefit.
Five patients of the total of births were classified as 
non-severe COVID-19 infection. In this group we observed 
two natural and one assisted vaginal birth, all of whom used 
Table 1. COVID-19 symptomatology in pregnant women and correlation with imaging and laboratory tests
Variables Total Temperature > 37.8ºC Cough Dyspnea Dysgeusia Anosmia Headache Myalgia
% (n) % (n) % (n) % (n) % (n) % (n) % (n)
70.0 (14) 65.0 (13) 15.0 (3) 20.0 (4) 30.0 (6) 25.0 (5) 35.0 (7)
Number of combined 
symptoms Total % (n) n n n n n n n
   1 20.0 (4) 2 0 0 0 0 0 2
   2 25.0 (5) 3 4 0 1 2 0 0
   3 40.0 (8) 6 6 2 1 2 3 4
   4 5.0 (1) 1 1 0 0 0 1 1
   5 10.0 (2) 2 2 1 2 2 1 0
Chest X-ray Total % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
   None 50.0 (10) 50.0 (7) 53.8 (7) 0.0 (0) 25.0 (1) 50.0 (3) 80.0 (4) 71.4 (5)
   No signs of COVID 20.0 (4) 21.4 (3) 30.8 (4) 33.3 (1) 50.0 (2) 33.3 (2) 0.0 (0) 0.0 (0)
   COVID pneumonia 30.0 (6) 28.6 (4) 15.4 (2) 66.7 (2) 25.0 (1) 16.7 (1) 20.0 (1) 28.6 (2)
Total
Mean (DE) Mean (DE) Mean (DE) Mean (DE) Mean (DE) Mean (DE) Mean (DE) Mean (DE)
Lymphopenia ^3/µL 1.66 (0.68) 1.59 (0.69) 1.67 (0.69) 1.00 (0.10)* 1.93 (0.72) 1.90 (0.56) 1.92 (0.79) 1.67 (0.98)
D- Dimer µg/mL 2.04 (3.36) 2.18 (3.91) 2.42 (4.11) 0.65 (0.58) 0.77 (0.68) 0.77 (0.68) 0.35 (0.01) 5.56 (6.03)*
C Reactive Protein (CRP) 
mg/dL 5.10 (7.64) 6.87 (8.71) 6.51 (9.38) 6.53 (5.69) 0.60 (0.37) 0.60 (0.37) 4.80 (5.37) 9.80 (12.22)*
*Higher value of analytic result according to each symptom
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epidural anesthesia and presented normal oxygen satura-
tion with values over 95% in pulse oximetry during labour. 
In this non-severe group, we didn´t find any episodes of 
intrapartum desaturation that indicated cesarean section 
and internal fetal heart monitoring was avoided. The indica-
tion of the two cesarean sections were an obstructed labour 
and a programmed cesarean section on maternal request 
for denied vaginal birth after cesarean.
The three rest of cesarean sections were done in severe 
cases of COVID-19 infection which we present below. 
The first case was a pregnant woman of 28 weeks with 
severe pneumonia upon admission and had a negative 
response to medical treatment. She needed invasive me-
chanical ventilation because of an oxygen saturation less 
than 90%. At that point we completed her pregnancy by 
cesarean section with general anesthesia and posterior 
intensive care admission (Fig. 1). 
The second case was an asymptomatic pregnancy of 
34 weeks with preterm rupture of membranes.  A cesar-
ean section was indicated because of breech presentation 
and done with spine anesthesia. During her puerperium 
she started with a rapid onset of severe respiratory distress 
with mild symptoms of COVID-19 infection. Without other 
thrombotic risk factors more than the cesarean section, she 
Table 2. Diagnosis, treatment and clinical evolution for all the pregnancies and severe cases
Total % (n = 20) Puerperium (n = 8) Severe cases (n = 3)
Variables % (n) % (n) % (n)
Age 
Media (DE) 34.9 (4.90) 35.3 (5.97) 36.0 (5.57)
Infectious transmission
  Unknown 50.0 (10) 62.5 (5) 0.0 (0)
  Symptomatic family 35.0 (7) 12.5 (1) 33.3 (1)
  In-Hospital 15.0 (3) 25.0 (2) 66.7 (2)
Diagnosis
  Rapid test positive 80.0 (12/15) 75.0 (6/8) 100 (3/3)
   RT PCR positive 85.0 (11/13) 50.0 (4/8) N.A. (0/0)
Pregestational morbidity 40.0 (8) 37.5 (3) 33.3 (1)
Gestational morbidity 30.0 (6) 62.5 (5) 66.7 (2)
Hospitalization 40.0 (8) 100.0 (8) 100 (3)
Intensive care 10.0 (2) 25.0 (2) 66.7 (2)
Respiratory distress on labor 5.0 (1) 12.5 (1) 33.3 (1)
Chest X-Ray
  None 50.0 (10) 0.0 (0) 0.0 (0)
  No signs of COVID-19 20.0 (4) 25.0 (2) 0.0 (0)
  COVID-19 pneumonia 30.0 (6) 75.0 (6) 100 (3)
Treatment
  Symptomatic 15.0 (3) 0.0 (0) 0 (0)
  Hydroxychloroquine 30.0 (6) 75.0 (6) 100 (3)
   Antibiotics 25.0 (5) 62.5 (5) 66.7 (2)
   Oxygen support 15.0 (3) 20.0 (2) 66.7 (2)
   Lopinavir/ritonavir 15.0 (3) 20.0 (2) 66.7 (2)
   Interferon 10.0 (2) 20.0 (2) 66.7 (2)
   LMWH 80.0 (16) 87.5 (6) 100 (3)
Lymphopenia 3/µL 
Media (DE) 1.66 (0.68) 1.30 (0.67) 0.80 (0.36)
D-dimer µg/ml 
Media (DE) 2.04 (3.36) 2.58 (4.07) 4.73 (6.76)
CRP mg/dl 
Media (DE) 5.10 (7.64) 6.96 (9.07) 15.63 (10.25)
N.A. — not accomplished
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had a pulmonary embolism combined with COVID-19 pneu-
monia diagnosed on CT scan (Fig. 1). 
The third case was a high-risk pregnancy by in vitro fer-
tilization with egg donation of an obese woman at 47 years 
of age. At 28 weeks of pregnancy she needed admission 
for hypertensive medical control and was diagnosed of 
severe preeclampsia. During her hospital stay she started 
with a combination of urologic infection and respiratory 
symptoms being diagnosed with a SARS-CoV-2 respiratory 
infection and urological sepsis. At 29 weeks she finished via 
cesarean section with general anesthesia on maternal ben-
efit because of a poor response to medical treatment with 
bad clinical and analytic evolution and she was taken to the 
intensive care unit (Fig. 1). On the 5th day of puerperium, she 
started with an early multiorgan failure with a massive post-
partum bleeding, so an abdominal hysterectomy was done. 
All the severe COVID-19 infection patients were man-
aged with prophylactic heparin treatment, hydroxychlo-
roquine and lopinavir/ritonavir. The pregnancies less 
than 34 weeks also received antibiotic treatment, oxygen 
support, interferon and antenatal corticosteroids for fetal 
lung maturation. 
The severe group presented a higher degree of analytic 
changes with the next medias: D-dimer 4.73 µg/mL, CRP 
15.63 mg/dL and lymphocytes 0.8 103/µL. 
After birth, 87.5% (7/8) of the cases had an early cord 
clamping. One case of skin to skin contact was allowed be-
cause the infection wasn’t known until the 3rd day after birth. 
All patients with a vaginal birth were accompanied by 
a relative with contact restrictions and PPE. All the non-
-severe cases were discharged without any puerperal com-
plications on the first 24 h postpartum.
About the neonatal outcomes we founded a medi-
um weigh of 2560.8 g (SD = 980.9), medium Apgar score 
at first minute of 8.25 (SD = 1.39) and at fifth minute of 
9.38 (SD = 0.92). About the type of reanimation of the new-
born was type I in 12.5% (1/8) and type III in 37.5% (3/8) and no 
reanimation in 50% (4/8). Breastfeeding was mainly maternal 
Figure 1. Radiologic findings of severe cases; (A–B) 29 years. 34 + 3 weeks. Pulmonary embolism and pneumonia at the third day of puerperium; 
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63.5% (5/8), one being directly from the maternal breast and 
the remaining four stimulated by breast pump until a nega-
tive COVID-19 result. All the neonates were accompanied 
by an asymptomatic relative with negative result of RT-PCR 
COVID-19. No clinical or serologic evidence of vertical trans-
mission was noticed, and no neonatal deaths were reported. 
The most relevant details of the obstetric and newborn 
results are resumed in the Table 3.
DISCUSSION    
Main findings
Our study demonstrates a relevant percentage of 20% 
(4/20) of pregnancies with just one symptom at the time of 
diagnosis. We observed a 60% (6/10) of radiologic findings 
of COVID-19 pneumonia in those patients studied with 
chest X-ray. 
During labour, two cesarean sections were done to im-
prove maternal oxygenation in two patients with severe 
clinical state. The remaining 75% (6/8) didn´t have any res-
piratory distress. 
Thromboprophylaxis treatment with (LMW) heparin 
was indicated in 80% (16/20) of the pregnancies regardless 
of the symptoms and D-dimer. However, we report a case 
of pulmonary thromboembolism during puerperium on 
a COVID-19 pneumonia.
The main recommendations about newborn manage-
ment as early cord clamping and mother–neonate isolation 
where done in 87.5% (7/8) cases. All neonates were accom-
panied by an asymptomatic relative with negative result of 
RT-PCR COVID-19. 
The postpartum period went without complications 
in 62.5% (5/8) so the mother could have an early hospital 
discharge in the first 24 hours. 
Strengths and limitations
This study is one of the first case series reports pub-
lished from Spain about the pandemic COVID-19 in 
pregnant women with symptoms and positive RT-PCR. 
Our hospital is part of a region in Spain, called Castil-
la La Mancha, with one of the highest mortality rates 
(113 deaths per 100,000 population). It was one of the 
most affected areas worldwide just surpassed by Madrid 
(Spain), Lombardy (Italy) and New York (USA) with 118, 
126 and 120 deaths per 100,000 each respectively, on 
the 25th of April [19]. 
Currently, there are few completed studies published 
with the recompilation of symptoms, information about 
clinical exposure, details about the pregnancy and postpar-
tum treatment as well as the obstetrical complications and 
critical care of the severe cases. We have detailed the type 
of quarantine, anesthesia, oxygen saturation during labour 
and breastfeeding of the newborns.
It must be taken into account that this study has ex-
cluded all pregnant woman with symptoms and compat-
ible radiological diagnose of COVID-19 pneumonia without 
Table 3. Obstetric and neonatal outcomes; n = 8
Variables Total % (n)
Gestational age
 < 34 weeks 25.0 (2)
  34–37 weeks 37.5 (3)
  > 37 weeks 37.5 (3)
Induction of labor 12.5 (1)
Intrapartum fever 12.5 (1)
Oxygen saturation on labor
  > 95% 75.0 (6)
  90-95% 12.5 (1)
  < 90% 12.5 (1)
Type of anesthesia 
  Spinal 25.0 (2)
  Epidural 50.0 (4)
  General 25.0 (2)
Type of birth
   Eutocic delivery 25.0 (2)
   Assisted vaginal delivery 12.5 (1)
   Caesarean section 62.5 (5)
Puerperium
  Pneumonia 75.0 (6)
  Pulmonary embolism 12.5 (1)
  Postpartum hemorrhage 25.0 (2)
Newborn weigh 
Media (DE) 2680.8 (980.9)
Early cord clamping 87.5 (7)
Skin to skin contact 12.5 (1)
Apgar minute 1 
Media (DE) 8.25 (1.39)
Apgar minute 5 
Media (DE) 9.38 (0.92)
Type of neonatal reanimation
   No reanimation 50.0 (4)
   Type I 12.5 (1)
   Type II 0 (0)
   Type III 37.5 (3)
Type of breastfeeding
  Artificial 37.5 (3)
Maternal with breast pump 
until negative 25.0 (2)
  Direct maternal 12.5 (1)
  Direct and breast pump 25.0 (2)
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confirmation via positive test for SARS-CoV-2. Consequence 
of the limitations of availability and diagnostic capacity of 
the tests for COVID-19 in Spain. 
Thromboprophylaxis in pregnant women during the 
pandemic has been one of the main challenges of the treat-
ment. During the period of the study, different views and 
protocols had been published and that is why just 16 out 
of 20 patients of our cohort had received LMW heparin. 
Interpretation
The optimal management of the pregnant women 
during the COVID-19 pandemic has been a big challenge 
for our obstetric department. At the beginning of the 
pandemic we needed to decide the suspicious symptoms 
in pregnant patients and the type of diagnostic tests that 
apply to them. After that, design the specific pathways 
of isolation for the maternal and neonatal care, doing 
staff training on the use of the PPE. Additionally, we have 
developed a hotline for the patients to report their symp-
toms before their arrival to the hospital, following the 
recommendations of the Center for Disease Control and 
prevention (CDC) [20].
 The need for implementation of a universal screening 
for all the pregnant women admitted to the labour room has 
been one of the main discussions of management. In hospi-
tals where it has been done, the prevalence of COVID-19 in 
asymptomatic patients published is 13.5% [21] and 13% [22]. 
In our department, during the period of the study, we have 
conducted a symptomatic screening excluding from our 
result ten patients with compatible symptoms but negative 
RT-PCR. We should take into account that we were limited 
by the local availability of the test for COVID-19 and their 
diagnostic accuracy. In our hospital each nasopharyngeal 
test was done with the kit GeneXPert SARS-CoV-2, giving 
the results of sensitivity and specificity of 35% and 96%. 
We also used an IgM/IgG rapid detection test. This kind of 
test could be criticized for an initial screening test because 
of the window period [23] but in our study, as it was used 
in symptomatic patients, it was useful. As a result of these 
factors, we decided to change since the last 20th of April to 
a universal screening of all the pregnancies in our obstetric 
department. 
About the symptoms analyzed, most of our pregnancies 
had fever and cough as their more common symptoms, like 
the results of Guan et al. and Wang et al. [24, 25]. We have 
considered anosmia and ageusia as compatible symptoms 
for COVID-19 [26–28], reporting in our series 4/20 pregnan-
cies with ageusia and 6/20 with anosmia. 
Thromboprophylaxis on the pregnant women with 
COVID-19 is recommended during pregnancy and puerper-
ium with LMW heparin, even though the studies are limited 
and presently unknown if the prophylactic or therapeutic 
anticoagulation has any impact in the result of the infection 
[15]. Even though the level of D-dimer could be normally 
higher during pregnancy, we consider COVID-19 infection 
and a higher level of D-dimer as the main thrombotic fac-
tors. They are related to a higher risk of venous thrombo-
embolism, severity and mortality of the disease [25, 29, 30]. 
In our study the severe cases had a D-dimer media of 
4.73 µg/mL (SD = 6.76) and a case of pulmonary embolism 
has been diagnosed although the treatment with 40 mg of 
heparin each 24 hours. 
The severity and mortality of the disease had been re-
lated to cardiovascular disease, diabetes, hypertensive dis-
orders and obesity (BMI ≥ 30) [31, 32]. In pregnant women 
with COVID-19, we should consider the impact on risk of 
hyperglycemias, weight gain and preeclampsia. Nowadays, 
there are no studies proving the relationship in pregnant 
women, but it is logical to suppose that those risk factors 
will worsen the pregnancies prognosis. The published stud-
ies report similar morbidity to our series [5, 6, 8, 33] and the 
reports of Breslin et al. [5] involving two maternal intensive 
care admissions of mothers with high BMI (> 35) leads one to 
question if COVID-19 increases the risk of severe morbidity 
in high risk pregnancies. 
We consider that the correct management of these 
high-risk pregnancies is the key and should be done by 
established protocols and with preventive measures like 
the prophylaxis with aspirin [10].
CONCLUSIONS
The symptomatic screening for COVID-19 on pregnant 
women is limited by two main factors: the percentage of 
pregnancies with just one symptom at hospitalization, in 
our cohort a 20%, and by the local availability and reliabil-
ity of the diagnostic test during the pandemic. Combining 
this information with the results reported in the literature 
of asymptomatic pregnancies with positive diagnostic test 
for COVID-19 and the implications of the misdiagnosing, 
we recommend to start routine testing for SARS-CoV-2 in 
obstetric patients at their hospitalization, regardless of their 
symptoms or the reason for admission. 
The symptoms and severity of the infection among 
pregnant women is normally between mild and moderate, 
so we consider appropriate the vaginal birth excepting 
those patients with bad clinical response or respiratory 
distress during labour. 
We recommend doing an big effort on the information 
for patients and a share decision making about the moth-
er–newborn isolation in positive cases of COVID-19 since 
the fear can lead a pregnant mother to minimize or even 
deny the suspicious symptoms. 
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